Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of once-daily modified-release hydrocortisone in primary adrenal insufficiency
2008-003990-42Phase 3Completed
- Sponsor
- DuoCort
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydrocortisone in Addison's disease, sponsored by DuoCort. Primary endpoints: Safety, tolerability and efficacy of once-daily oral modified-release hydrocortisone and Safety of rescue therapy during minor intercurrent illnesses. Started Jul 2008; status: completed.
02
Drugs
hydrocortisone
03
Conditions
Addison's disease
Beyond the preview
Go deeper on 2008-003990-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003990-42.